User

Infant Bacterial Therapeutics AB (publ)

IBT-B.ST

Biotechnology · Healthcare

Price

kr 61.00

+1.00 (+1.67%)

Market Cap

kr 794.1M

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Infant Bacterial Therapeutics (IBT) is a Swedish biotech company focused on developing a drug to prevent a serious gut disease in premature babies called necrotizing enterocolitis, or NEC. NEC is a life-threatening condition that affects the intestines of newborns, and there are currently no approved drugs specifically designed to prevent it. IBT's lead product, IBP-9414, contains a bacteria strain called Lactobacillus reuteri and is given to premature infants in neonatal intensive care units.

IBT does not yet sell any products, so it earns no revenue today — all of its funding comes from selling shares to investors. The company is based in Stockholm, Sweden, and its work is focused primarily on clinical trials in the United States and Europe. Its main competitive advantage is its focus on a condition with no approved treatment, but the biggest risk is that its drug could fail in late-stage clinical trials, which would likely be devastating for the company given it has no other products generating income.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

-37.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$49M/ year

↓ Declining (-59% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

13.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 years

$132M cash & investments

$132M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-28.0%

Weak — -28.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial